

BIOFIL CHEMICALS AND PHARMACEUTICALS LIMITED

CIN: L24233MP1985PLC002709

Registered Office: 11/12, Sector E Sanwer Road, Indore-452015 (M.P.)

Tel. 0731-2723016; Email id- bcplcompliance@gmail.com;

Website- www.biofilgroup.net; Fax: 0731-2723017

Date: 30th May, 2023

To, The Secretary (DCS/Compliance), Corporate Relationship Department, BSE Limited (DCS/Compliance) Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai-400001	To, The Secretary (Listing/Compliance), National Stock Exchange of India Limited, Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Mumbai – 400051
---	---

Sub: Submission of Audited Financial Results for the Quarter as well as year ended 31st March, 2023 in terms of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Ref: BIOFIL CHEMICALS AND PHARMACEUTICALS LIMITED (BSE Scrip Code: 524396; NSE Symbol: BIOFILCHEM; ISIN: INE829A01014)

Dear Sir/Madam,

In compliance with Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are here enclosing the Audited Financial Results for the quarter as well as year ended 31st March, 2023 duly approved by the Board of Directors at its meeting held today i.e. Tuesday, 30th May, 2023 together with Audit Report thereon, Statement of assets and liabilities, Cash Flow Statement & declaration by the Managing Director of Company pursuant to second proviso of Regulation 33(3)(d) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 .

Further above said results shall also be submitted in XBRL mode within 24 hours from the conclusion of Board Meeting.

The financial results shall also be uploaded on the Company's website i.e. www.biofilgroup.net and on the website of the Stock Exchanges i.e., at www.bseindia.com & www.nseindia.com and extracts of the aforesaid results shall also be published in Hindi (Vernacular) and widely circulated English Newspaper.

You are requested to take on record the above said financial results for your reference and record.

Thanking you.

Yours Faithfully,

FOR, BIOFIL CHEMICALS AND PHARMACEUTICALS LIMITED

SHWETA VERMA
COMPANY SECRETARY & COMPLIANCE OFFICER
M. NO. A70184

Enclosure: Audited Financial Results along with auditor's report for the quarter as well as year ended 31st March, 2023



**Independent Auditor's Report on Quarterly Financial Results and Year to Date
Results of the Company Pursuant to the Regulation 33 and 52 of the SEBI (Listing Obligations
and
Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations")**

To,
The Board of Directors
Biofil Chemicals And Pharmaceuticals Limited
Indore (M.P.)

Opinion

We have audited the quarterly financial results of **Biofil Chemicals and Pharmaceuticals Limited** ("The Company") for the quarter ended March 31, 2023 and the year to date results for the period April 1, 2022 to March 31, 2023, attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 and 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us, these quarterly financial results as well as the year to date results:

- i. are presented in accordance with the requirements of Listed Regulations in this regard; and
- ii. give a true and fair view in conformity with the recognition and measurement principles laid down in the applicable accounting standards and other accounting Principles generally accepted in India; of the net profit and other comprehensive Income and other financial information for the Quarter ended March 31 2023 as well as the year to date results for the period from April 1, 2022 to March 31, 2023.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013 (the Act). Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Financial Results section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial results under the provisions of the Companies Act, 2013 and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Management's Responsibilities for the Financial Results

These quarterly financial results as well as the year to date financial results have been prepared on the basis of the interim financial statements. The Company's Board of Directors are responsible for the preparation of these financial results that give a true and fair view of the net profit/loss and other comprehensive income and other financial information in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, 'Interim Financial Reporting' prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 and 52 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records





accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the financial results, the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are also responsible for overseeing the Company's financial reporting process.


Auditor's Responsibilities for the Audit of the Financial Results

Our objectives are to obtain reasonable assurance about whether the financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could

reasonably be expected to influence the economic decisions of users taken on the basis of these financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial results or, if such





disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.

- Evaluate the overall presentation, structure and content of the financial results, including the disclosures, and whether the financial results represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Other Matter

The Statement includes the results for the quarter ended March 31, 2023 being the balancing figure between the audited figures in respect of the full financial year ended March 31, 2023 and the published unaudited year-to-date figures up to the third quarter of the current financial year, which were subject to a limited review by us, as required under the Listing Regulations.

For MAHESHWARI & GUPTA

Chartered Accountants

F.R.N.: 006179C



CA. SUNIL MAHESHWARI

Partner

M.NO : 403346

PLACE : INDORE

DATE : 30th May, 2023

UDIN : 23403346BGUKFP9085



BIOFIL CHEMICALS AND PHARMACEUTICALS LIMITED

CIN NO. L24233MP1985PLC002709


Regd Off: 11/12, Sector-'E' Sanwer Road, Industrial Area, Indore (M.P.) 452015

Email Id: bcplcompliance@gmail.com Phone No. 0731-2426718, 2723016-17 Website: www.biofilgroup.net

(Amount in Lakhs except EPS)

Statement of Audited Financial Results for the Quarter and Year ended 31st March 2023

Sr No.	Particulars	Quarter Ended		Year Ended		
		March 31, 2023	December 31, 2022	March 31, 2022	March 31, 2023	March 31, 2022
		Audited	Un-Audited	Audited	Audited	Audited
I	Revenue from Operation	1361.57	149.44	164.55	3003.52	2238.23
II	Other Income	3.29	2.37	3.01	9.70	15.03
III	Total Income	1364.86	151.81	167.56	3013.22	2253.26
IV	Expenses					
	(a) Cost of materials consumed	132.66	115.96	40.30	391.835	226.76
	(b) Purchases of stock-in-trade	1181.58	2.75	5.27	2370.63	1360.27
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(36.90)	(22.34)	51.07	(20.13)	359.01
	(d) Employee benefits expense	17.87	14.93	23.59	62.38	78.67
	(e) Finance Cost	1.00	1.06	1.02	4.25	4.06
	(f) Depreciation and Amortisation Expense	10.85	10.69	11.86	42.91	42.75
	(g) Other expenses					
	1. Manufacturing Expenses	14.86	10.79	14.55	47.34	41.48
	2. Administrative Expenses	10.36	3.10	14.92	29.50	34.85
	3. Selling and Distribution Expenses	0.29	1.49	0.66	5.21	3.92
	Total expenses	1332.57	138.43	163.25	2933.93	2151.77
V	Profit/ (Loss) before exceptional items and tax	32.29	13.37	4.31	79.30	101.49
VI	Exceptional Items	0.00	0.00	0.00	0.00	0.00
VII	Profit/ (Loss) before tax	32.29	13.37	4.31	79.30	101.49
VIII	Tax expense:					
	(1) Current tax	11.17	3.36	2.61	23.00	27.10
	(2) Deferred tax	0.26	0.00	4.55	0.26	4.55
	Total Tax expenses	11.43	3.36	7.16	23.26	31.65
IX	Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement	0.00	0.00	0.00	0.00	0.00
X	Profit/(Loss) for the period from continuing operation	20.86	10.01	(2.85)	56.04	69.84
XI	Profit/(Loss) for the period for dis-continued operation	0.00	0.00	0.00	0.00	0.00
XII	Tax expenses of discontinued operation	0.00	0.00	0.00	0.00	0.00
XIII	Profit/(Loss) for the period for dis-continued operation after tax	0.00	0.00	0.00	0.00	0.00
XIV	Profit/ (Loss) for the period	20.86	10.01	(2.85)	56.04	69.84
XV	Other Comprehensive Income	0.00				
	A) (I) Items that will not be reclassified to Profit or Loss	(12.91)	0.00	1.35	(12.91)	1.35
	(II) Income Tax relating to items that will not be reclassified to Profit or Loss	3.25	0.00	(0.34)	3.25	(0.34)
	B) (i) Items that will be reclassified to Profit or Loss	0.00	0.00	0.00	0.00	0.00
	(II) Income Tax relating to items that will be reclassified to Profit or Loss	0.00	0.00	0.00	0.00	0.00
XVI	Total Comprehensive Income for the period (XIII + XIV) (Comprising Profit or Loss and other Comprehensive income for the period)	11.20	10.01	(1.84)	46.38	70.86
XVII	Paid-Up equity share capital (face value of Rs 10/- each)	1627.38	1627.38	1627.38	1627.38	1627.38
XVIII	Reserves (Excluding Revaluation Reserve)				(273.44)	(319.82)
XIX	Earnings per equity shares (for continuing operation):					
	(1) Basic (Rs)	0.07	0.06	(0.01)	0.29	0.44
	(2) Diluted (Rs)	0.07	0.06	(0.01)	0.29	0.44




XX	Earnings Per Equity Share (for discontinued operation) .					
	(1) Basic (Rs)	0.00	0.00	0.00	0.00	0.00
	(2) Diluted (Rs)	0.00	0.00	0.00	0.00	0.00
XXI	Earnings Per Equity Share (for continuing & discontinued operation)					
	(1) Basic (Rs)	0.07	0.06	(0.01)	0.29	0.44
	(2) Diluted (Rs)	0.07	0.06	(0.01)	0.29	0.44


- 1 The above Audited results for the Quarter and financial year ended March 31, 2023 were reviewed and recommended by the Audit Committee and approved by the Board of Directors in it's meeting held on 30-05-2023. The above results have been audited by statutory Auditors of the company in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The Company's Management has exercised necessary due diligence to ensure that the financial results provide a true and fair view of its affairs.
- 2 This statement has been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 and other recognized accounting practices and policies to the extent applicable.
- 3 The figures for the quarter ended 31st March 2023 and 31st March 2022 are the balancing figures between the audited figures in respect of the full financial year and the years to date figures up to the third quarter.
The Company has reported segment wise information as per Indian Accounting Standard (Ind AS-108). The Operations of the Company are conducted within India, there is no separate reportable geographical segment and the company reported the following business segments
- 4 a. Pharma Product
b. Chemicals Division
- 5 Statutory Auditors of the Company has carried out audit of the books of accounts for the financial year 2022-2023 and issued us an Audit Report with unmodified opinion on Audited Financial Year for the quarter/year ended on 31st March, 2023, therefore the Company is not required to give statement of Impact of Audit Qualification for Audit Report with modified opinion
- 6 The aforesaid audited financial Results will be uploaded on the Company's website www.biofilgroup.net and will also be available on the websites of the Stock exchanges i.e. www.bseindia.com and www.nseindia.com for the benefit of shareholders and investors
- 7 The figures of the previous period / year have been re-stated/ re-grouped / re-arranged/ reclassified and / or recasted wherever found necessary.
- 8 The Statement of Assets & Liabilities as on at March 31, 2023 is annexed with the results along with the Statement of Cash Flow.

Date : 30/05/2023
Place : Indore

FOR BIOFIL CHEMICALS AND PHARMACEUTICALS LIMITED



RAMESH SHAH
CHAIRMAN & MANAGING DIRECTOR
(DIN: 00028819)





BIOFIL CHEMICALS AND PHARMACEUTICALS LIMITED

CIN NO. L24233MP1985PLC002709

Regd Off: 11/12, Sector-'E' Sanwer Road, Industrial Area, Indore (M.P.) 452015

Email id: bcpcompliance@gmail.com Phone No. 0731-2426718, 2723016-17 Website: www.biofilgroup.net


Audited statement of assets & liabilities as at 31-03-2023

Sr No.	Particulars	(Amount in Lakhs)	
		As at 31/03/2023 Audited	As at 31/03/2022 Audited
A	ASSETS		
1	Non-current assets:		
	(a) Property, Plant & Equipment	900.07	941.93
	(b) Capital work in Progress		
	(c) Investment Property		
	(d) Goodwill		
	(e) Other Intangible assets		
	(f) Intangible Assets under development		
	(g) Biological Assets other than bearer plants		
	(h) Financial Assets:		
	i. Investments		
	ii. Trade receivables		
	iii. Loans		
	iv. Others (to be specified)		
	(i) Deferred tax assets (net)		
	(j) Other Non- Current Assets		
	Sub-total - Non-current assets	900.07	941.93
2	Current assets		
	(a) Inventories	121.34	129.32
	(b) Financial Assets:		
	(i) Investment		
	(ii) Trade receivables	2,050.27	717.37
	(iii) Cash and cash equivalents	2.60	8.50
	(iv) Bank balances other than (iii) above	1.17	6.00
	(v) Loans		
	(vi) Others (to be specified)		
	(c) Current Tax Asset (Net)		
	(d) Other Currents Assets	65.12	70.12
	Sub-total - Current assets	2,240.50	931.30
	TOTAL - ASSETS	3,140.57	1,873.22
B	EQUITY AND LIABILITIES		
1	Equity		
	(i) Equity Share Capital	1,627.38	1,627.38
	(ii) Other Equity	102.77	56.39
	Sub-total- Equity	1,730.15	1,683.77
2	Liabilities		
	Non-current Liabilities :		
	a. Financial Liabilities		
	(i) Borrowings		
	(ia) Lease Liabilities		
	(ii) Trade Payable		
	(a) total outstanding dues of micro enterprises and small enterprises; and		
	(b) total outstanding dues of creditors other than micro enterprises and small Enterprises.		
	(iii) other Financial Liabilities (other than those specified in item (b), to be specified)		
	b. Provisions		
	c. Deferred tax liabilities (net)	37.87	39.98
	d. Other Non-current Liabilities		
	Sub-total - Non-current liabilities	1,768.02	1,723.75
3	Current liabilities		
	a. Financial Liabilities		
	(i) Borrowings	52.23	46.47
	(ia) Lease Liabilities		
	(ii) Trade Payables :-		
	(a) total outstanding dues of micro enterprises and small enterprises; and		
	(b) total outstanding dues of creditors other than micro enterprises and small Enterprises.	1,264.99	59.63
	(iii) other Financial Liabilities [other than those specified in item (C)]		
	b. Other Current Liabilities	32.33	16.28
	c. Provisions	23.00	27.10
	d. Current Tax Liabilities (Net)		
	Sub-total - Current liabilities	1,372.55	149.48
	TOTAL - EQUITY AND LIABILITIES	3,140.57	1,873.22

Date: 30-05-2023
Place: INDORE

FOR BIOFIL CHEMICALS AND PHARMACEUTICALS LIMITED

Ramesh Shah
RAMESH SHAH
CHAIRMAN & MANAGING DIRECTOR
(DIN: 00028819)



Statement of cash flows for the year ended 31st March 2023

Sr No.	Particulars	(Amount in Lakhs)	
		For the year ended March 31, 2023	For the year ended March 31, 2022
		Audited	Audited
A)	Cash flow from operating activities		
	Profit before tax	79.30	101.49
	Adjustments to reconcile profit before tax to net cash used in operating activities	0.00	0.00
	Depreciation of property, plant and equipment	42.91	42.75
	Finance cost	4.25	4.06
	Impact of Gratuity considered in OCI	(9.66)	1.01
	Net (gain)/ loss on derivative contracts on account of Ind AS adjustments	116.81	149.31
	Provision for doubtful advances/debts		
	Working capital adjustments	0.00	0.00
	(Increase)/ Decrease in Inventory	7.97	305.14
	(Increase)/ Decrease in Trade Receivable, Current	(1332.90)	1004.42
	(Increase)/ Decrease in Trade Receivable, Non Current	0.00	0.00
	(Increase)/ Decrease in other current assets	5.00	75.75
	(Increase)/ Decrease in other non current assets	0.00	0.00
	(Increase)/ Decrease in other financial assets, current	0.00	0.00
	(Increase)/ Decrease in other financial assets, non-current	0.00	0.00
	Increase/ (Decrease) in trade payables- Current	1205.36	(1525.57)
	Increase/ (Decrease) in trade payables- Non-Current	0.00	0.00
	Increase/ (Decrease) in other financial liabilities- current	16.05	1.90
	Increase/ (Decrease) in other financial liabilities- Non-current	0.00	0.00
	Increase/ (Decrease) in other liabilities	(6.21)	(1.29)
	Cash generated from operations	12.08	9.67
	Tax Expenses		
	Current tax	(23.00)	(27.10)
	Deferred tax	(1.14)	(4.02)
	Adjustment of tax relating to earlier periods	0.88	(0.53)
	Net cash flows from operating activities (A)	(11.18)	(21.98)
B)	Cash flow from investing activities		
	Payment for purchase and construction of property, plant and equipment	(1.06)	(6.99)
	Proceeds from sale of property, plant and equipment	0.00	0.00
	(Increase)/ Decrease in other bank balances	0.00	0.00
	Interest received	0.00	0.00
	Net cash flows from investing activities (B)	(1.06)	(6.99)
C)	Cash flow from financing activities		
	Increase/(decrease) in Borrowings	5.76	3.48
	Deemed Investment by Holding Company	0.00	0.00
	Finance cost	(4.25)	(4.06)
	Net cash flows from financing activities (C)	1.51	(0.58)
	Net increase / (decrease) in cash and cash equivalents	(10.73)	(29.55)
	Cash and cash equivalents at the beginning of the year	14.49	44.05
	Cash and cash equivalents at the end of the year	3.76	14.49
	Increase / (Decrease) in cash and cash equivalents	(10.73)	(29.55)

Date: 30/05/2023

Place: INDORE

FOR BIOFIL CHEMICALS AND PHARMACEUTICALS LIMITED

Ramesh Shah



RAMESH SHAH
CHAIRMAN & MANAGING DIRECTOR
(DIN: 00028819)

Segmentwise Revenue, Results and Capital Employed for year ended 31st March 2023

S.No.	Particulars	(Amount in Lakhs)				
		Quarter Ended			Year Ended	
		March 31, 2023	December 31, 2022	March 31, 2022	March 31, 2023	March 31, 2022
		Audited	Un-Audited	Audited	Audited	Audited
1	Segment Revenue					
	Pharma Division	1,215.16	1.33	20.42	2,419.61	1,900.52
	Chemical Division	146.41	148.11	144.13	583.91	337.71
	Net sales/Income From Operations	1,361.57	149.44	164.55	3,003.52	2,238.23
2	Segment Results (Profit)(+)/ Loss (-) before tax and interest					
	Pharma Division	14.01	(11.95)	(11.06)	(14.58)	98.70
	Chemical Division	19.13	26.35	15.75	97.91	4.63
	Total Segment Profit Before Tax	33.14	14.40	4.69	83.33	103.33
	Interest Income	0.11	0.03	0.65	0.16	2.22
	Interest Expenses	0.95	1.06	1.03	4.19	4.06
	Profit Before Tax	32.29	13.37	4.31	79.30	101.49
3	Capital Employed					
	Segment Assets (A)					
	Pharma Division	1,705.77	873.87	678.10	1,705.77	678.10
	Chemical Division	1,434.80	1,382.80	1,195.13	1,434.80	1,195.13
		3,140.57	2,256.66	1,873.22	3,140.57	1,873.22
	Total (A)					
	Segment Liabilities (B)					
	Pharma Division	1,142.60	346.31	86.53	1,142.60	86.53
	Chemical Division	267.83	191.71	102.93	267.83	102.93
	Total (B)	1,410.42	538.02	189.46	1,410.42	189.46
4	Total Capital Employed (Segment Assets-Segment Liabilities)					
	Pharma Division	563.17	527.56	591.56	563.17	591.56
	Chemical Division	1,166.98	1,191.09	1,092.20	1,166.98	1,092.20
	Total Capital Employed (Segment Assets-Segment Liabilities)	1,730.15	1,718.64	1,683.77	1,730.15	1,683.77


Date: 30-05-2023

Place: Indore

FOR BIOFIL CHEMICALS AND PHARMACEUTICALS LIMITED

Ramesh Shah

RAMESH SHAH
CHAIRMAN & MANAGING DIRECTOR
(DIN: 00028819)



BIOFIL CHEMICALS AND PHARMACEUTICALS LIMITED

CIN: L24233MP1985PLC002709

Registered Office: 11/12, Sector E Sanwer Road, Indore-452015 (M.P.)

Tel. 0731-2723016; Email id- bcplcompliance@gmail.com;

Website- www.biofilgroup.net; Fax: 0731-2723017

Date: 30th May, 2023

To, The Secretary (DCS/Compliance) , Corporate Relationship Department, BSE Limited (DCS/Compliance) Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai-400001	To, The Secretary (Listing/Compliance) , National Stock Exchange of India Limited, Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Mumbai – 400051
---	---

Sub: Submission of declaration regarding unmodified opinion of the Auditors on Annual Audited Financial Results of the Company for the financial year ended 31st March, 2023 as per second proviso to Regulation 33(3)(d) of SEBI (Listing Obligations and Disclosure Requirement) Regulations, 2015

Ref: BIOFIL CHEMICALS AND PHARMACEUTICALS LIMITED (BSE Scrip Code: 524396; NSE Symbol: BIOFILCHEM; ISIN: INE829A01014)

Dear Sir/Madam,

Pursuant to Regulation 33(3)(d) of the SEBI (Listing Obligations and Disclosure Requirement) Regulations, 2015 as amended from time to time, I, the undersigned do hereby declare that in the Audit Report accompanying the Annual Audited Financial Results of **BIOFIL CHEMICALS AND PHARMACEUTICALS LIMITED** for the financial year ended on 31st March, 2023, the Statutory Auditor M/s Maheshwari & Gupta, Chartered accountants did not express any modified opinion/audit qualification or other reservation and accordingly, the Statement on Impact of Audit Qualifications is not required to be given.

You are requested to please consider and take on record the same.

Thanking You,

Yours Faithfully,

FOR BIOFIL CHEMICALS AND PHARMACEUTICALS LIMITED

RAMESH SHAH
CHAIRMAN AND MANAGING DIRECTOR
(DIN: 00028819)